Tamtuvetmab

• Description:

  Tamtuvetmab (AT-005) is a caninised blontuvetmab against CD52. Tamtuvetmab increases progression-free survival (PFS), exhibits in vivo efficacy in dogs with naïve T-cell lymphoma (LSA) . Tamtuvetmab has been approved by veterinary[1][2].

• Product Name Alternative:

  AT-005

• UNSPSC:

  12352203

• Target:

  NF-κB

• Type:

  Inhibitory Antibodies

• Related Pathways:

  NF-κB

• Applications:

  Cancer-programmed cell death

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/tamtuvetmab.html

• Purity:

  97

• Solubility:

  10 mM in DMSO

• Smiles:

  [Tamtuvetmab]

• Molecular Weight:

  (146.346 kDa)

• References & Citations:

  [1]Musser ML, et al. Randomised trial evaluating chemotherapy alone or chemotherapy and a novel monoclonal antibody for canine T-cell lymphoma: A multicentre US study. Vet Rec Open. 2022 Nov 1;9 (1) :e49. |[2]Rhodes L. Changing innovation into a registered product: From concept to regulatory approval. Theriogenology. 2018 May;112:75-81.

• Shipping Conditions:

  Dry Ice

• Storage Conditions:

  Store at -80°C for 2 years

• Scientific Category:

  Inhibitory Antibodies

• Clinical Information:

  No Development Reported

• CAS Number:

  1608122-71-9